Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma
Conditions: Recurrent Head and Neck Cancer; Recurrent Head and Neck Squamous Cell Carcinoma; Recurrent Head and Neck Carcinoma; Metastatic Head-and-neck Squamous-cell Carcinoma; Metastatic Head and Neck Cancer; HNSCC Interventions: Drug: Ramucirumab; Drug: Pembrolizumab Sponsors: Washington University School of Medicine; Eli Lilly and Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Head and Neck Cancer | HNSCC | Research | Skin Cancer | Squamous Cell Carcinoma